PharmaTher Holdings Ltd. is a specialty psychedelic pharmaceutical company, which engages in the research, development and commercialization of ketamine and novel microneedle patches for delivering psychedelics to treat neuropsychiatric, neurodegenerative, and pain disorders. The company is headquartered in Toronto, British Columbia. The company went IPO on 2020-10-09. The firm develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The firm is also commercializing PharmaPatch (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases. The firm is in the development of programs for the delivery of KETARX (ketamine) in a patch and on-body pump for mental health, pain and medical countermeasures indications.
